Neuraltus Pharmaceuticals
Stage
Series B | AliveTotal Raised
$43.79MLast Raised
$14.94M | 7 yrs agoAbout Neuraltus Pharmaceuticals
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Missing: Neuraltus Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Neuraltus Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Neuraltus Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Neuraltus Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Neuraltus Pharmaceuticals Patents
Neuraltus Pharmaceuticals has filed 12 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/15/2016 | 12/12/2017 | Water treatment, Oxidizing agents, Sodium compounds, Disinfectants, Mass spectrometry | Grant |
Application Date | 1/15/2016 |
|---|---|
Grant Date | 12/12/2017 |
Title | |
Related Topics | Water treatment, Oxidizing agents, Sodium compounds, Disinfectants, Mass spectrometry |
Status | Grant |
Latest Neuraltus Pharmaceuticals News
Aug 9, 2018
05:24 EDT 9 Aug 2018 | BioPortfolio Reports Summary Neuraltus Pharmaceuticals Inc Neuraltus is a biopharmaceutical company that develops and commercializes therapeutics for neurodegenerative diseases. The company offers products under clinical development that include NP001 and others. It develops macrophage which is based on the recent understanding of the fundamental role of inflammation and macrophage activation in chronic neurodegenerative diseases. The company's products are used for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis , Parkinson 's disease, and Alzheimer's disease and inherited metaboloic disorders such as fabry's disease and gaucher's disease. Neuraltus is headquartered in San Bruno, California, the US. Neuraltus Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Neuraltus Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Neuraltus Pharmaceuticals's headquarters?
Neuraltus Pharmaceuticals's headquarters is located at 1001 Bayhill Drive, San Bruno.
What is Neuraltus Pharmaceuticals's latest funding round?
Neuraltus Pharmaceuticals's latest funding round is Series B.
How much did Neuraltus Pharmaceuticals raise?
Neuraltus Pharmaceuticals raised a total of $43.79M.
Who are the investors of Neuraltus Pharmaceuticals?
Investors of Neuraltus Pharmaceuticals include Latterell Venture Partners, VantagePoint Capital Partners, Adams Street Partners and Qualifying Therapeutic Discovery Project.
Who are Neuraltus Pharmaceuticals's competitors?
Competitors of Neuraltus Pharmaceuticals include Radius, Humanetics, Kiadis Pharma, Asteres, Intarcia Therapeutics, Athenex, Reata Pharmaceuticals, CymaBay Therapeutics, iPierian, Onconova Therapeutics and 33 more.
Compare Neuraltus Pharmaceuticals to Competitors
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Nano-Mite Technologies is engaged in R&D to control obesity using nanotechnology that alters the body's metabolic rate and increase the cell's ability to convert sugar to energy. Per the company, Nano-Mite's technnology could lead to futures in the treatment of traumatic central nervous system damage and neurodegenerative disorders.
Alacrity Biosciences is a biopharmaceutical company focused on acquiring, developing and commercializing therapeutics to treat ophthalmic diseases that threaten vision and reduce patient quality of life.
Phytomedics is a biopharmaceutical company based in New Jersey with a broad portfolio of novel compounds for chronic diseases. The lead compound is in clinical development and has shown extraordinary results in clinical trials for the treatment of auto immune disorders like rheumatoid arthritis. The company's platform technology is the basis of their large portfolio of novel therapeutic compounds.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.